STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTLA
  4. [Form 4] Intellia Therapeutics, Inc. Insider Trading Activity

Intellia Therapeutics (NTLA) CEO reports option exercises, share sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Intellia Therapeutics' President and CEO, who is also a director, reported stock option exercises and related share sales in company stock. On 12/11/2025, the reporting person exercised options to acquire 49,959 shares of common stock at an exercise price of $ 6.83 and sold 49,959, 32,832 and 5,355 shares in separate transactions with weighted average prices of $ 9.49, $ 9.47 and $ 9.59, respectively.

On 12/12/2025, additional options for 8,557 shares were exercised at $ 6.83. These option awards were granted under the company’s 2015 Stock Option and Incentive Plan and had vested in full as of 12/11/2025. The filing notes that the sales occurred automatically under a Rule 10b5‑1 trading plan adopted on 09/11/2025. Following these transactions, the reporting person beneficially owns 1,047,485 shares directly and 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.

Positive

  • None.

Negative

  • None.
Insider LEONARD JOHN M
Role President and CEO
Sold 88,146 shs ($836K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 8,557 $0.00 --
Exercise Common Stock 8,557 $6.83 $58K
Exercise Stock Option (right to buy) 49,959 $0.00 --
Exercise Common Stock 49,959 $6.83 $341K
Sale Common Stock 49,959 $9.49 $474K
Sale Common Stock 32,832 $9.47 $311K
Sale Common Stock 5,355 $9.59 $51K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 1,047,485 shares (Direct); Common Stock — 58,415 shares (Indirect, By Trust)
Footnotes (1)
  1. The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. Shares held by the John M. Leonard 2015 Irrevocable Trust. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEONARD JOHN M
(Last) (First) (Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2025 M 49,959 A $6.83 1,127,074 D
Common Stock 12/11/2025 S(1) 49,959 D $9.49(2) 1,077,115 D
Common Stock 12/11/2025 S(1) 32,832 D $9.47(3) 1,044,283 D
Common Stock 12/11/2025 S(1) 5,355 D $9.59(4) 1,038,928 D
Common Stock 12/12/2025 M 8,557 A $6.83 1,047,485 D
Common Stock 58,415 I By Trust(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $6.83 12/11/2025 M 49,959 (6) 02/03/2026 Common Stock 49,959 $0.00 8,557 D
Stock Option (right to buy) $6.83 12/12/2025 M 8,557 (6) 02/03/2026 Common Stock 8,557 $0.00 0 D
Explanation of Responses:
1. The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
5. Shares held by the John M. Leonard 2015 Irrevocable Trust.
6. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.
/s/ James Basta, attorney-in-fact 12/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Intellia Therapeutics (NTLA) report in this filing?

The reporting person exercised stock options at $ 6.83 on 12/11/2025 and 12/12/2025 for 49,959 and 8,557 shares, and sold 49,959, 32,832, and 5,355 shares of common stock on 12/11/2025.

Were the NTLA insider stock sales made under a Rule 10b5-1 trading plan?

Yes. The explanation states that the sales reported occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on 09/11/2025.

How many Intellia Therapeutics (NTLA) shares does the insider own after these transactions?

After the reported transactions, the reporting person beneficially owns 1,047,485 shares of common stock directly and 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.

What stock options were exercised in this Intellia Therapeutics (NTLA) filing?

Stock options with an exercise price of $ 6.83 were exercised for 49,959 shares on 12/11/2025 and 8,557 shares on 12/12/2025. These options, issued under the 2015 Stock Option and Incentive Plan, had vested in full as of 12/11/2025 and had an expiration date of 02/03/2026.

At what prices were Intellia Therapeutics (NTLA) shares sold in this insider report?

Shares were sold on 12/11/2025 at weighted average prices of $ 9.49, $ 9.47, and $ 9.59, with underlying transactions ranging from $ 9.33 to $ 9.65 as described in the footnotes.

How is indirect ownership structured for the reporting person in this NTLA filing?

The filing shows 58,415 shares of common stock held indirectly, identified as shares held by the John M. Leonard 2015 Irrevocable Trust.